Rue de la Rôtisserie 8
About Combioxin SACombioxin SA is a clinical-stage company that develops innovative anti-virulence treatments for serious bacterial infections, including those caused by antibiotic-resistant strains. The lead candidate, CAL02, is a first-in-class, clinical-stage non-antibiotic liposomal drug that neutralizes bacterial toxins, protects against infection severity and complications, and improves antibiotic efficacy.
Founders: Frédéric Lajaunias and Samareh Lajaunias Azeredo da Silveira
CMO: Antonio Perez
Please click here for clinical trial information..
8 articles with Combioxin SA
5/7/2020Pharma and life sciences companies from across the globe provide updates on their business and pipelines.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
Combioxin Highlights Results from Successful CAL02-001 First-in-Human Trial Evaluating CAL02 in Severe Pneumonia at ESICM 2018
Combioxin SA announced an Oral Presentation highlighting successful first-in-human clinical results with CAL02 in severe pneumonia patients in ICU, at the ESICM’s annual congress, LIVES 2018, in Paris today.
Combioxin SA announced today that first-in-human clinical results with CAL02 in severe pneumonia patients in ICU will be presented during the ESICM’s annual congress, LIVES 2018, taking place October 20-24, 2018 in Paris, France.
Combioxin Release: Data Monitoring Committee Unanimously Recommends Continuation Of Combioxin First-In-Human Clinical Trial With CAL02 In Patients With Severe Pneumococcal Pneumonia
Combioxin Escalates To High Dose In CAL02-001 Trial In Patients With Severe Pneumococcal Pneumonia Following IDMC's Positive Recommendation